Heron Therapeutics (HRTX) Operating Leases (2019 - 2025)
Historic Operating Leases for Heron Therapeutics (HRTX) over the last 7 years, with Q3 2025 value amounting to $780000.0.
- Heron Therapeutics' Operating Leases rose 4942.53% to $780000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $780000.0, marking a year-over-year increase of 4942.53%. This contributed to the annual value of $2.8 million for FY2023, which is 4908.17% down from last year.
- As of Q3 2025, Heron Therapeutics' Operating Leases stood at $780000.0, which was up 4942.53% from $1.5 million recorded in Q2 2025.
- Heron Therapeutics' Operating Leases' 5-year high stood at $13.8 million during Q1 2021, with a 5-year trough of $522000.0 in Q3 2024.
- Moreover, its 5-year median value for Operating Leases was $4.8 million (2023), whereas its average is $5.5 million.
- Its Operating Leases has fluctuated over the past 5 years, first crashed by 8524.17% in 2024, then skyrocketed by 4942.53% in 2025.
- Over the past 5 years, Heron Therapeutics' Operating Leases (Quarter) stood at $8.0 million in 2021, then tumbled by 31.23% to $5.5 million in 2022, then crashed by 49.08% to $2.8 million in 2023, then plummeted by 81.36% to $522000.0 in 2024, then soared by 49.43% to $780000.0 in 2025.
- Its Operating Leases stands at $780000.0 for Q3 2025, versus $1.5 million for Q2 2025 and $522000.0 for Q3 2024.